Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 4/20 | 0.82 |
| ▸ | NPC1 | O15118 | 3/20 | 0.82 |
| ▸ | RAB9A | P51151 | 3/20 | 0.82 |
| ▸ | MTOR | P42345 | 1/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | FBP1 | P09467 | 10/20 | 0.53 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | ABL2 | P42684 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2742581 | 1.00 | VCP (0.82) | VCPNPC1RAB9AMTORKDM4E | |
| SCHEMBL16211885 | 0.90 | NPC1 (1.00) | VCPNPC1RAB9AMTORKDM4E | |
| SCHEMBL744717 | 0.90 | NPC1 (1.00) | VCPNPC1RAB9AMTORKDM4E | |
| SCHEMBL744716 | 0.90 | NPC1 (1.00) | VCPNPC1RAB9AMTORKDM4E | |
| SCHEMBL30577771 | 0.90 | NPC1 (1.00) | VCPNPC1RAB9AMTORKDM4E | |
| SCHEMBL13799666 | 0.87 | VCP (0.77) | VCPNPC1RAB9AMTORFBP1 | |
| Piperonal SCHEMBL6073053 | 0.84 | NPC1 (0.88) | VCPNPC1RAB9AMTORKDM4E | |
| Piperonal SCHEMBL6073058 | 0.84 | NPC1 (0.88) | VCPNPC1RAB9AMTORKDM4E | |
| SCHEMBL18579319 | 0.83 | VCP (0.61) | VCPNPC1RAB9AMTORFBP1 | |
| SCHEMBL29434317 | 0.83 | VCP (0.61) | VCPNPC1RAB9AMTORFBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365093-B2 | Endothelin antagonists | ABBOTT LABORATORIES (US) | 2008-04-29 | — | — | US | disclosed |
| US-7208517-B1 | Endothelin antagonists | ABBOTT LABORTORIES (US) | 2007-04-24 | — | — | US | disclosed |
| US-20060229280-A1 | Endothelin antagonists | ABBVIE INC. | 2006-10-12 | — | — | US | disclosed |
| EP-0885215-B1 | NOVEL BENZO-1,3-DIOXOLYL- AND BENZOFURANYL SUBSTITUTED PYRROLIDINE DERIVATIVES AS ENDOTHELIN ANTAGONISTS | ABBOTT LAB (US) | 2006-04-19 | — | — | EP | disclosed |
| EP-1609790-A2 | Benzo-1,3-dioxolyl- and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists | Abbott Laboratories (US) | 2005-12-28 | — | — | EP | disclosed |
| US-6946481-B1 | Endothelin antagonists | ABBOTT LABORATORIES (US) | 2005-09-20 | — | — | US | disclosed |
| US-6887865-B2 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2005-05-03 | — | — | US | disclosed |
| US-6864368-B2 | N-heterocyclic derivatives as NOS inhibitors | BERLAX LABORATORIES, INC. (US) | 2005-03-08 | — | — | US | disclosed |
| US-6864263-B2 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2005-03-08 | — | — | US | disclosed |
| US-6849739-B2 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2005-02-01 | — | — | US | disclosed |
| EP-1003740-A2 | PYRROLIDINE-3-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGOISTS | Abbott Laboratories (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999006397-A2 | PYRROLIDINE-3-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ABBOTT LABORATORIES (US) | 1999-02-11 | — | — | WO | disclosed |
| EP-0885215-A1 | NOVEL BENZO-1,3-DIOXOLYL- AND BENZOFURANYL SUBSTITUTED PYRROLIDINE DERIVATIVES AS ENDOTHELIN ANTAGONISTS | Abbott Laboratories (US) | 1998-12-23 | — | — | EP | disclosed |
| US-5767144-A | Endothelin antagonists | ABBOTT LABORATORIES (US) | 1998-06-16 | — | — | US | disclosed |
| US-5731434-A | CARDIOVASCULAR DISORDERS | ABBOTT LABORATORIES (US) | 1998-03-24 | — | — | US | disclosed |
| WO-1997030045-A1 | NOVEL BENZO-1,3-DIOXOLYL- AND BENZOFURANYL SUBSTITUTED PYRROLIDINE DERIVATIVES AS ENDOTHELIN ANTAGONISTS | ABBOTT LABORATORIES (US) | 1997-08-21 | — | — | WO | disclosed |
| EP-0776324-A1 | ENDOTHELIN ANTAGONISTS | Abbott Laboratories (US) | 1997-06-04 | — | — | EP | disclosed |
| US-5622971-A | PIPERIDINE DERIVATIVES; HYPOTENSIVE AGENTS | ABBOTT LABORATORIES (US) | 1997-04-22 | — | — | US | disclosed |
| WO-1996006095-A1 | ENDOTHELIN ANTAGONISTS | ABBOTT LABORATORIES (US) | 1996-02-29 | — | — | WO | disclosed |
| US-4001244-A | 1-ARYL-3,4-DIHYDRO-2(1H)-ISOQUINOLINE CARBONYL CHLORIDES | G. D. SEARLE & CO. (US) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229280-A1 | Endothelin antagonists | EDNRA, EDNRB, ECE1 | VCP 2389/4885NPC1 2347/4885RAB9A 2605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.